Tests Adderall XR added to brain stimulation for depression
Tests Adderall XR alongside brain stimulation in adults with major depressive disorder.
Plain-language title generated from the registry record
Registry title: Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
Key facts
- Where
- Los Angeles, United StatesSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT04509102, who can take part
Where in United States
- UCLA SemelLos Angeles, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, Los Angeles
- Trial code
- NCT04509102
- Record updated
- 3 February 2026
- Original description
This study analyzes the affects or Adderall extended-release (XR) in Subjects receiving brain stimulation therapy for the treatment of Major Depressive Disorder. Subjects will be assigned by chance to active or placebo group. Active group will be asked to take one 15 mg pill once daily of Adderall XR (amphetamine) and the Placebo group will be asked take an identical appearing tablet/capsule, one tablet by mouth daily. The placebo tablet has no active ingredients and has no affect on the body or mind. With the exception of the study drug, all other study activities between both groups will be identical. Subjects will use the assigned study drug two weeks before therapy and throughout the first 10 therapy treatments. A total of seven(7) visits will be required for screening, drug assignment, and completion of mood assessments. This study will enroll a total of 30 Subjects.Read full original descriptionShow less
*Full Title of the Submission: Psychostimulant Augmentation of Repetitive TMS (rTMS) for the Treatment of Major Depressive Disorder: A Randomized, Placebo-controlled Clinical Trial
This study analyzes the affects or Adderall extended-release (XR) in Subjects receiving brain stimulation therapy for the treatment of Major Depressive Disorder. Subjects will be assigned by chance to active or placebo group. Active group will be asked to take one 15 mg pill once daily of Adderall XR (amphetamine) and the Placebo group will be asked take an identical appearing tablet/capsule, one tablet by mouth daily. The placebo tablet has no active ingredients and has no affect on the body or mind. With the exception of the study drug, all other study activities between both groups will be identical. Subjects will use the assigned study drug two weeks before therapy and throughout the first 10 therapy treatments. A total of seven(7) visits will be required for screening, drug assignment, and completion of mood assessments. This study will enroll a total of 30 Subjects.
Inclusion: All subjects will be between the ages of 18-65 and will meet DSM-V criteria for a current episode of major depressive disorder; Meet criteria for treatment resistance as defined by lack of response to two prior antidepressant trials at adequate dosage and duration. Participants may use any psychotropic medications other than psychostimulants or benzodiazepines, and may continue these medications during the study; The outside treating psychiatrist must agree that enrollment in the study is safe and acceptable for the subject.
Exclusion: Current use of psychostimulant medication; Current use of an Monoamine oxidase inhibitors (MAOI) or use of an MAOI within the past two weeks; Lifetime diagnosis of bipolar affective disorder; Lifetime diagnosis of major depressive disorder with psychotic features, schizophrenia, schizoaffective disorder, or any other psychotic disorder; History of psychotic symptoms; Lifetime diagnosis of substance use disorder; History of stimulant misuse or abuse; History of hypersensitivity to Adderall XR; History of intolerance of any psychostimulant medication; Presence of motor tics or family history of tic disorder; Symptomatic cardiovascular disease including hypertension, coronary artery disease, arteriosclerosis, cardiomyopathy, or arrhythmia; Structural cardiac abnormalities; Family history of sudden cardiac death in a first degree relative; History of epilepsy or seizure; History of stroke; History of brain tumor; Inability to give informed consent; Active substance abuse; Anxiety, tension, or agitation that is of sufficient severity to make it difficult for the subjects to tolerate psychostimulants and/or 10 Hz rTMS treatment; Current use of benzodiazepines; Pregnancy, breastfeeding, or plans to become pregnant during the study period; Glaucoma; Hyperthyroidism; Presence of any metal in the head; Presence of pacemaker or medical devices implanted close to the site of magnetic stimulation.